Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial (Q42915836)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 5, 2010

Language	Label	Description	Also known as
English	Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial	scientific article published on September 5, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Bengt Glimelius

8

object named as

Bengt Glimelius

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Michael Gubanski

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Anders Johnsson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Eva Fernebro

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Lianna Kadar

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ingegerd Karlberg

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Petra Flygare

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ake Berglund

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Pehr A. Lind

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820984

7 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20820984

7 July 2024

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

5 September 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20820984

7 July 2024

full work available at URL

https://link.springer.com/content/pdf/10.1007%2Fs10120-010-0553-4.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820984

7 July 2024

http://link.springer.com/content/pdf/10.1007/s10120-010-0553-4.pdf

Portable Document Format

1 reference

10.1007/S10120-010-0553-4

https://api.crossref.org/works/10.1007/S10120-010-0553-4

7 July 2024

http://link.springer.com/article/10.1007/s10120-010-0553-4/fulltext.html

1 reference

10.1007/S10120-010-0553-4

https://api.crossref.org/works/10.1007/S10120-010-0553-4

7 July 2024

http://link.springer.com/content/pdf/10.1007/s10120-010-0553-4

1 reference

10.1007/S10120-010-0553-4

https://api.crossref.org/works/10.1007/S10120-010-0553-4

7 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

155-161

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-010-0553-4

21 January 2018

Chemotherapy for gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-010-0553-4

21 January 2018

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10120-010-0553-4

21 January 2018

Docetaxel-based chemotherapy in the treatment of gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A systematic overview of chemotherapy effects in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cochrane Database of Systematic Reviews

5

2

CD004064

author name string

A.D. Wagner

publication date

2005

1 reference

10.1007/S10120-010-0553-4

https://api.crossref.org/works/10.1007/S10120-010-0553-4

7 July 2024

Cancer Treatment Reports

20

63

1727

author name string

J.H. Goldie

publication date

1979

1 reference

10.1007/S10120-010-0553-4

https://api.crossref.org/works/10.1007/S10120-010-0553-4

7 July 2024

Identifiers

10.1007/S10120-010-0553-4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42915836&oldid=2218407821"